Join Visiopharm at USCAP 2021
Get the insights and inspiration you need at USCAP 2021 with Visiopharm, a world leader in AI-driven digital precision pathology software.
On the agenda
- Exhibitor seminar: Join Visiopharm’s Chief Clinical and Regulatory Officer, Esther Abels and their Chief Diagnostic Officer, Dirk Vossen, live as they discuss the challenges and innovations in tissue biomarker analysis for diagnosis on 17 March, followed by a live Q&A session. In the Q&A Visiopharm will be unveiling their new Qualitopix early access program, aimed at standardizing tissue biomarker staining. The labs that join the program will be at the forefront of biomarker quality and standardization. See the full event details here.
- Virtual booth: Gain access to their interactive virtual booth to get to know Visiopharm better and be among the first to find out about their staining quality and standardization programs.
- Book a chat: Don’t miss the chance to get your digital pathology questions answered by their team of experts. You can pre-book a one-to-one chat with them via their online calendar here until 14 March, or schedule a time directly at their virtual booth from 15 – 17 March.
Have a great USCAP 2021!
About Visiopharm
Visiopharm® is a world leader in AI-driven Digital Pathology solutions. Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.
AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, and the United States. Follow Visiopharm on LinkedIn and Twitter. For other news, visit the Visiopharm Newsroom.
Source: Visiopharm
